

Biol 485: Discovery and biochemical characterization of plasmodium thioredoxin reductase inhibitors from an antimalarial set
(questions written by Tyler Bradshaw, Daniel Saiku, and Chad Sumulong;
answers provided by Chad Sumulong)

1. What is Thioredoxin reductase (TrxR) and what is its relationship with thioredoxin (Trx)? Why is TrxR a good drug target?

Thioredoxin (trx) is a substrate of Thioredoxin reductase, an enzyme that helps relieve oxidative stress. Researchers thought that TrxR was a good drug target because of its differences between it and the human enzyme, which is mentioned in question 2.

2. What species-specific differences do the authors cite as their rationale for the possibility of designing drugs to selectively target the *P. falciparum* TrxR?

Between the two species enzymes, the mammalian TrxR contained a selenocysteine compound in its active site, which gave researchers the opportunity to create a drug target that could selectively inhibit the bacterial enzyme.

3. What were the roles of Insulin and glucose-6-phosphate dehydrogenase in this study?

Insulin and glucose-6-phosphate dehydrogenase were used in the enzyme assays to help keep the K_m of the substrates at optimal levels. This was done to allow researchers to see a noticeable difference in enzyme activity due to drug inhibition.

4. What is a K_m ? What do different values of K_m tell us about substrate affinity?

The K_m is translated to be the substrate concentration level at half of the enzyme's kinetic maximum activity (V_{max}). A substrate with a lower K_m has high affinity while a substrate with high K_m has lower affinity.

5. Referring to Table 1, which compound is the most potent inhibitor of *P. falciparum* TrxR? Explain.

According to Table 1, compound 3 is the most potent inhibitor because of its higher pIC_{50} value. This means that at a lower concentration, it is able to inhibit the enzyme by 50%, while the other drugs need higher concentrations to inhibit the enzyme 50%.

6. After reading last week's paper, Baldwin et al. (2005) [PMID: 15795226], the class realized many of the frustrations of target-based assays. How do the authors of this paper rationalize their choice of target-based assay? (Hint: Discussion section)

The researchers rationalize that although the compounds have been shown to inhibit enzymatic activity in whole cell assays, using target-based assays can help bridge the gap and provide a definitive link between the whole cell assays and the compounds. This leads to a better understanding of how to create drugs, make them selective, etc.